Abstract:Objective To investigate the clinical pharmacokinetics (PK) and pharmacodynamics (PD) of gemifloxacin tablet in healthy Chinese volunteers and to provide evidences for optimal clinical dosing.Methods Twenty volunteers were enrolled in the randomized (1∶1) double-blind study,and divided into administration group and control group.Each group received multiple oral doses of 320 mg of gemifloxacin tablet or placebo.The plasma and urine samples for gemifloxacin were analyzed by igh-performance liquid chromatogram (HPLC)-fluorometric method. The minimum inhibition concentrations (MIC) of gemifloxacin against 190 clinical isolates were determined by broth microdilution method.The fAUC0～24 h/MIC and fCmax/MIC,with target value of 25 and 5,were used as the indices to evaluate PK and PD characteristics of gemifloxacin. The cumulative fraction of response (CFR) of gemifloxacin against each bacterium and the probability of target attainment (PTA) under various MIC level were evaluated using Monte Carlo simulation following multiple administration at steady state.Results The Cmax of gemifloxacin after once-daily oral doses for 7 days were (1.55 ±0.32) μg/mL and (1.57±0.31) μg/mL for the first and last dose,while the AUC0～24 h were (7.91±1.52) and (8.91±1.15) h · μg · mL-1,respectively.The accumulation factor was 1.13±0.05.The time-profile of gemifloxacin could be described using two-compartment model and the half-life of distribution and elimination phase were (0.64 ± 0.17) and (7.10 ± 2.10) h,respectively. The cumulative urinary excretion rates within 24 h of gemifloxacin were 34.83 ％ and 38.95 ％ for the first and the last dose,respectively.PD study showed that the MIC90 of gemifloxacin were 0.25 mg/L and 0.125 mg/L against Streptococcus pneumoniae and Moraxelle catarrhalis,respectively,while the MIC90 was 2 mg/L against Hemophilus influenza. However,most of Klebsiella pneumoniae and methicillin-resistant Staphylococcus aureus (MRSA) were resistant to gemifloxacin ( MIC90 ＞ 32mg/L).The PTA values of fAUC0～24 h/MIC and fCmax/MIC of gemifloxacin 320 mg daily for 7 days were close to 100％ when MIC was ≤0.06 mg/L.Conclusions Gemifloxacin is rapidly absorbed after oral administration of single doses in healthy Chinese volunteers,and the plasma concentration could reach steady state at the third day,while a minimal accumulation is shown after consecutive 7 days dosing.The PK/PD analysis suggests that the favorable clinical and bacteriological efficacy could be obtained when using this regimen in treatment of sensitive patients with community-acquired pneumonia and acute exacerbation of chronic obstructive pulmonary disease.

Pharmacokinetics of Gatifloxacin Tablet in Healthy Volunteers

Pharmacokinetics of gatifloxacin mesylate tablet in healthy volunteers after a single oral administration

Study on Pharmacokinetics of Multi-Dose of Oral Gatifloxacin Methanesulfonate Tablets in Healthy Volunteers

A study on multi-dose pharmacokinetics of gatifloxacin mesylate in healthy volunteers

Clinical pharmacokinetics and pharmacodynamics of gemifloxacin in healthy Chinese volunteers following multiple oral administration

A Double-Blind, Randomized Controlled Clinical Study:Gatifloxacin Vs Levofloxacin in Treatment of 98 Patients with Urinary Tract Infections

Adverse Drug Reactions Induced by Gatifloxacin:Analysis of 866 Cases During 2003～2006

Clinical randomized controlled trials of Gatifloxacin injection in the treatment of bacterial infections of lower respiratory tract and urinary tract

A Randomized Controlled Clinical Study on a New Quinolone,gatifloxacin, in the Treatment of Respiratory Tract Infections

Pharmacokinetics of Moxifloxacin Hydrochloride Tablets in Healthy Volunteers

A Multicenter, Single-Blind, Randomized Comparison of Sequential Therapy of Gatifloxacin Versus Levofloxacin in the Treatment of Bacterial Infections

Clinical pharmacokinetics of gemifloxacin following single oral dose administration in healthy Chinese male subjects

Bacteriological Efficacy of Gatifloxacin Methanesulfonate Tablet on Acute Bacterial Infections

The Serum Bactericidal Activity of Gatifloxacin

Double-blind Randomized Controlled Clinical Trial on Gatifloxacin Versus Levofloxacin Injection for Treating Acute Bacterial Infections

Clinical Randomized Controlled Trials of Gatifloxacin Injection in Treatment of Bacterial Infections of Respiratory Tract

Pharmacokinetics of pazufloxacin single dose intravenous in healthy volunteers

Randomized Controlled Study on Gatifloxacin and Levofloxacin Injection in the Treatment of Acute Gonococcal Urinary and Reproductive Tract Infections

Pharmacokinetics of Antofloxacin Hydrochloride, a Novel Fluoroquinolone, after Single-Dose Intravenous Administration in Healthy Chinese Male Volunteers.

Pharmacokinetics of antofloxacin hydrochloride, a new fluoroquinolone antibiotic, after single oral dose administration in Chinese healthy male volunteers.

A follow-up study of effects of gatifloxacin on blood glucose in inpatients